surmount 3 tirzepatide Clinical trials of subcutaneous (SURMOUNT-1, -2 and -3 ECO 2026: SURMOUNT-MAINTAIN proves tirzepatide

A recommendation is not an approval, and FDA approved claims remain off limits

While the researchers did not find evidence that people who lost more body weight had a larger reduction in cardiovascular risk, they did find that larger decreases in waist circumference (a more sensitive marker of visceral fat) accounted for roughly a third of the reduction in cardiac risk in the semaglutide group, still leaving most of the benefit unexplained by changes in body composition

11HSD1 Inhibition with AZD4017 improves lipid profiles and lean muscle mass in idiopathic intracranial hypertension

A practical step is to run targeted genetic panels, basic metabolic labs, and a semen DNA fragmentation test before starting therapy